High drug attrition rates remain a critical issue in oncology drug development. A series of
steps during drug development must be addressed to better understand the …

Cancer is a complex disease that is characterized by an uncontrolled growth and spread of
abnormal cells. Drug development in oncology is particularly challenging and is associated …

Mathematical modeling has become a valuable tool that strives to complement conventional
biomedical research modalities in order to predict experimental outcome, generate new …

The application of pharmacokinetic (PK) and pharmacodynamic (PD) modeling in drug
development has emerged during the past decades and it is has been suggested that the …

Purpose Physiologically based pharmacokinetic (PBPK) modeling, a mathematical
modeling approach which uses a pharmacokinetic model to mimick human physiology to …

Introduction: Modeling and simulation have become important means of answering
questions relevant to the development of a drug, making it possible to assess risks early and …

Progress in an understanding of the genetic basis of cancer coupled to molecular
pharmacology of potential new anticancer drugs calls for new approaches that are able to …

In oncology trials, overall survival (OS) is considered the most reliable and preferred
endpoint to evaluate the benefit of drug treatment. Other relevant variables are also …

The success of the drug development program heavily relies on the rational drug design
with appropriate choice of drug and dosing regimen. This requires a good understanding of …

Contemporary models in the field of pharmacokinetic–pharmacodynamic (PK–PD) modeling
often incorporate the fundamental principles of capacity limitation and operation of turnover …